Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 4/20 | 0.55 |
| ▸ | TSHR | P16473 | 1/20 | 0.55 |
| ▸ | HCRTR1 | O43613 | 2/20 | 0.51 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.49 |
| ▸ | HPGD | P15428 | 2/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | APEX1 | P27695 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.46 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.46 |
| ▸ | NAAA | Q02083 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9977945 | 0.83 | HCRTR1 (0.48) | HTTTSHRHCRTR1EPHX1HPGD | |
| SCHEMBL18259815 | 0.81 | NPC1 (0.52) | HTTTSHREPHX1HPGDMAPK1 | |
| SCHEMBL30038068 | 0.81 | HTT (0.51) | HTTTSHRHCRTR1HPGDMAPK1 | |
| SCHEMBL28873883 | 0.81 | HTT (0.51) | HTTTSHRHCRTR1HPGDMAPK1 | |
| SCHEMBL29798859 | 0.80 | NPC1 (0.58) | HTTTSHREPHX1HPGDMAPK1 | |
| SCHEMBL6273378 | 0.79 | HTT (0.86) | HTTTSHRHPGDKMT2AAPEX1 | |
| SCHEMBL18918566 | 0.79 | SMN1; SMN2 (0.57) | EPHX1KMT2ALMNAMAPTNAAA | |
| SCHEMBL28810855 | 0.78 | HTT (0.77) | HTTTSHRHCRTR1HPGDKMT2A | |
| SCHEMBL18271811 | 0.77 | EPHX1 (0.46) | EPHX1KMT2AKDM4E | |
| SCHEMBL23610299 | 0.77 | HTT (0.75) | HTTTSHRHCRTR1EPHX1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9890178-B2 | Azabenzimidazoles as respiratory syncytial virus antiviral agents | JANSSEN SCIENCES IRELAND UC (IE) | 2018-02-13 | — | — | US | disclosed |
| US-9890178-B2 | Azabenzimidazoles as respiratory syncytial virus antiviral agents | JANSSEN SCIENCES IRELAND UC (IE) | 2018-02-13 | — | — | US | disclosed |
| US-20160237096-A1 | AZABENZIMIDAZOLES AS RESPIRATORY SYNCYTIAL VIRUS ANTIVIRAL AGENTS | JANSSEN SCIENCES IRELAND UC (IE) | 2016-08-18 | — | — | US | disclosed |
| US-20160237096-A1 | AZABENZIMIDAZOLES AS RESPIRATORY SYNCYTIAL VIRUS ANTIVIRAL AGENTS | JANSSEN SCIENCES IRELAND UC (IE) | 2016-08-18 | — | — | US | disclosed |
| US-9321767-B2 | Azabenzimidazoles as respiratory syncytial virus antiviral agents | JANSSEN SCIENCES IRELAND UC (IE) | 2016-04-26 | — | — | US | disclosed |
| US-9321767-B2 | Azabenzimidazoles as respiratory syncytial virus antiviral agents | JANSSEN SCIENCES IRELAND UC (IE) | 2016-04-26 | — | — | US | disclosed |
| EP-2651933-B1 | AZABENZIMIDAZOLES AS RESPIRATORY SYNCYTIAL VIRUS ANTIVIRAL AGENTS | JANSSEN SCIENCES IRELAND UC (IE) | 2016-03-16 | — | — | EP | disclosed |
| CN-103347881-B | As the azabenzimidazoles of respiratory syncytial virus antiviral agent | JANSSEN R&D IRELAND (IE) | 2015-10-21 | — | — | CN | disclosed |
| US-20150073012-A1 | AZABENZIMIDAZOLES AS RESPIRATORY SYNCYTIAL VIRUS ANTIVIRAL AGENTS | JANSSEN SCIENCES IRELAND UC (IE) | 2015-03-12 | — | — | US | disclosed |
| US-20150073012-A1 | AZABENZIMIDAZOLES AS RESPIRATORY SYNCYTIAL VIRUS ANTIVIRAL AGENTS | JANSSEN SCIENCES IRELAND UC (IE) | 2015-03-12 | — | — | US | disclosed |
| US-8916605-B2 | Compounds and methods for treating cancer and viral infections | JUPITER BIOMEDICAL RESEARCH, INC. | 2014-12-23 | — | — | US | disclosed |
| US-8916605-B2 | Compounds and methods for treating cancer and viral infections | JUPITER BIOMEDICAL RESEARCH, INC. | 2014-12-23 | — | — | US | disclosed |
| US-20130261151-A1 | AZABENZIMIDAZOLES AS RESPIRATORY SYNCYTIAL VIRUS ANTIVIRAL AGENTS | JANSSEN R & D IRELAND (IE) | 2013-10-03 | — | — | US | disclosed |
| CN-102438618-A | Compounds and methods for treating cancer and viral infections | GOFF HILL LTD | 2012-05-02 | — | — | CN | disclosed |
| US-20120035238-A1 | COMPOUNDS AND METHODS FOR TREATING CANCER AND VIRAL INFECTIONS | GOFF HILL LIMITED (BB) | 2012-02-09 | — | — | US | disclosed |
| US-20120035238-A1 | COMPOUNDS AND METHODS FOR TREATING CANCER AND VIRAL INFECTIONS | GOFF HILL LIMITED (BB) | 2012-02-09 | — | — | US | disclosed |
| US-20120035238-A1 | COMPOUNDS AND METHODS FOR TREATING CANCER AND VIRAL INFECTIONS | GOFF HILL LIMITED (BB) | 2012-02-09 | — | — | US | disclosed |
| EP-2403496-A1 | COMPOUNDS AND METHODS FOR TREATING CANCER AND VIRAL INFECTIONS | Goff Hill Limited (BB) | 2012-01-11 | — | — | EP | disclosed |
| WO-2010099600-A1 | COMPOUNDS AND METHODS FOR TREATING CANCER AND VIRAL INFECTIONS | TUCKER WILLIAM G (CA) | 2010-09-10 | — | — | WO | disclosed |
| WO-2010099600-A1 | COMPOUNDS AND METHODS FOR TREATING CANCER AND VIRAL INFECTIONS | TUCKER WILLIAM G (CA) | 2010-09-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160237096-A1 | AZABENZIMIDAZOLES AS RESPIRATORY SYNCYTIAL VIRUS ANTIVIRAL AGENTS | AZI2, ZC3HAV1, ZC3HAV1L | HTT 4845/4885TSHR 4377/4885HCRTR1 4797/4885 |
| US-20150073012-A1 | AZABENZIMIDAZOLES AS RESPIRATORY SYNCYTIAL VIRUS ANTIVIRAL AGENTS | ZC3HAV1, AZI2, ZC3HAV1L | HTT 4850/4885TSHR 4359/4885HCRTR1 4820/4885 |
| US-20120035238-A1 | COMPOUNDS AND METHODS FOR TREATING CANCER AND VIRAL INFECTIONS | TP53, RNASE1, FURIN | HTT 4428/4885TSHR 4722/4885HCRTR1 3080/4885 |
| US-20130261151-A1 | AZABENZIMIDAZOLES AS RESPIRATORY SYNCYTIAL VIRUS ANTIVIRAL AGENTS | ZC3HAV1, AZI2, ZC3HAV1L | HTT 4850/4885TSHR 4359/4885HCRTR1 4820/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.